Protocol Ledger

NCT04588311 · Phase III · RECRUITING

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

Interventional Phase III clinical trial protocol NCT04588311 sponsored by Australian and New Zealand Intensive Care Research Centre in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-09 Enrollment: 2,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04588311
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04588311
Protocol FieldVerified Registry Value
NCT IdentifierNCT04588311
Consolidated Lead SponsorAustralian and New Zealand Intensive Care Research Centre
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment2,500 participants (ESTIMATED)
Registered Start Date2020-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04588311
Hospital Research SiteLocationSite Profile
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Liverpool HospitalLiverpool, AustraliaOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI